GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cizzle Biotechnology Holdings PLC (LSE:CIZ) » Definitions » Gross Margin %

Cizzle Biotechnology Holdings (LSE:CIZ) Gross Margin % : 0.00% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cizzle Biotechnology Holdings Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Cizzle Biotechnology Holdings's Gross Profit for the six months ended in Jun. 2024 was £0.00 Mil. Cizzle Biotechnology Holdings's Revenue for the six months ended in Jun. 2024 was £0.00 Mil. Therefore, Cizzle Biotechnology Holdings's Gross Margin % for the quarter that ended in Jun. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Cizzle Biotechnology Holdings's Gross Margin % or its related term are showing as below:


During the past 13 years, the highest Gross Margin % of Cizzle Biotechnology Holdings was 37.01%. The lowest was 33.16%. And the median was 36.01%.

LSE:CIZ's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.89
* Ranked among companies with meaningful Gross Margin % only.

Cizzle Biotechnology Holdings had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Cizzle Biotechnology Holdings was 0.00% per year.


Cizzle Biotechnology Holdings Gross Margin % Historical Data

The historical data trend for Cizzle Biotechnology Holdings's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cizzle Biotechnology Holdings Gross Margin % Chart

Cizzle Biotechnology Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cizzle Biotechnology Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cizzle Biotechnology Holdings's Gross Margin %

For the Biotechnology subindustry, Cizzle Biotechnology Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cizzle Biotechnology Holdings's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cizzle Biotechnology Holdings's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Cizzle Biotechnology Holdings's Gross Margin % falls into.


;
;

Cizzle Biotechnology Holdings Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Cizzle Biotechnology Holdings's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Cizzle Biotechnology Holdings's Gross Margin for the quarter that ended in Jun. 2024 is calculated as


Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Cizzle Biotechnology Holdings  (LSE:CIZ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Cizzle Biotechnology Holdings had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Cizzle Biotechnology Holdings Gross Margin % Related Terms

Thank you for viewing the detailed overview of Cizzle Biotechnology Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cizzle Biotechnology Holdings Business Description

Traded in Other Exchanges
N/A
Address
C/o SGH Secretaries Limited, 60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Cizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is correlated with early stage lung cancer.

Cizzle Biotechnology Holdings Headlines